Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 3
2004 4
2005 2
2006 1
2007 3
2008 4
2009 1
2010 2
2011 2
2012 6
2013 6
2014 4
2015 6
2016 4
2017 5
2018 6
2019 2
2020 4
2021 7
2022 3
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Harnessing Antibody Polyspecificity for Cancer Immunotherapy.
Pashov A, Murali R, Makhoul I, Karbassi B, Kieber-Emmons T. Pashov A, et al. Among authors: murali r. Monoclon Antib Immunodiagn Immunother. 2022 Oct;41(5):290-300. doi: 10.1089/mab.2022.0025. Monoclon Antib Immunodiagn Immunother. 2022. PMID: 36306515 Review.
Neuropilin 1 regulates bone marrow vascular regeneration and hematopoietic reconstitution.
Termini CM, Pang A, Fang T, Roos M, Chang VY, Zhang Y, Setiawan NJ, Signaevskaia L, Li M, Kim MM, Tabibi O, Lin PK, Sasine JP, Chatterjee A, Murali R, Himburg HA, Chute JP. Termini CM, et al. Among authors: murali r. Nat Commun. 2021 Nov 30;12(1):6990. doi: 10.1038/s41467-021-27263-y. Nat Commun. 2021. PMID: 34848712 Free PMC article.
Stimulation of antitumor immunity by FoxP3-targeting PROTAC.
Wang Y, Zhang Y, Su S, Tamukong P, Murali R, Kim HL. Wang Y, et al. Among authors: murali r. Biomed Pharmacother. 2023 Jul;163:114871. doi: 10.1016/j.biopha.2023.114871. Epub 2023 May 12. Biomed Pharmacother. 2023. PMID: 37182514 Free article.
Targeting erbB receptors.
Cai Z, Zhang H, Liu J, Berezov A, Murali R, Wang Q, Greene MI. Cai Z, et al. Among authors: murali r. Semin Cell Dev Biol. 2010 Dec;21(9):961-6. doi: 10.1016/j.semcdb.2010.09.005. Epub 2010 Sep 17. Semin Cell Dev Biol. 2010. PMID: 20850557 Free PMC article. Review.
Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis.
Yan Y, Zhou B, Qian C, Vasquez A, Kamra M, Chatterjee A, Lee YJ, Yuan X, Ellis L, Di Vizio D, Posadas EM, Kyprianou N, Knudsen BS, Shah K, Murali R, Gertych A, You S, Freeman MR, Yang W. Yan Y, et al. Among authors: murali r. Nat Commun. 2022 Feb 3;13(1):669. doi: 10.1038/s41467-022-28340-6. Nat Commun. 2022. PMID: 35115556 Free PMC article.
ONECUT2 Activates Diverse Resistance Drivers of Androgen Receptor-Independent Heterogeneity in Prostate Cancer.
Qian C, Yang Q, Rotinen M, Huang R, Kim H, Gallent B, Yan Y, Cadaneanu RM, Zhang B, Kaochar S, Freedland SJ, Posadas EM, Ellis L, Vizio DD, Morrissey C, Nelson PS, Brady L, Murali R, Campbell MJ, Yang W, Knudsen BS, Mostaghel EA, Ye H, Garraway IP, You S, Freeman MR. Qian C, et al. Among authors: murali r. bioRxiv [Preprint]. 2023 Oct 12:2023.09.28.560025. doi: 10.1101/2023.09.28.560025. bioRxiv. 2023. PMID: 37905039 Free PMC article. Preprint.
Targeting prostate tumor low-molecular weight tyrosine phosphatase for oxidation-sensitizing therapy.
Stanford SM, Nguyen TP, Chang J, Zhao Z, Hackman GL, Santelli E, Sanders CM, Katiki M, Dondossola E, Brauer BL, Diaz MA, Zhan Y, Ramsey SH, Watson PA, Sankaran B, Paindelli C, Parietti V, Mikos AG, Lodi A, Bagrodia A, Elliott A, McKay RR, Murali R, Tiziani S, Kettenbach AN, Bottini N. Stanford SM, et al. Among authors: murali r. Sci Adv. 2024 Feb 2;10(5):eadg7887. doi: 10.1126/sciadv.adg7887. Epub 2024 Jan 31. Sci Adv. 2024. PMID: 38295166 Free PMC article.
86 results